πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Ikena Oncology, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

AnaptysBio, Inc.

AnaptysBio, Inc. logo
Market Cap: Medium
Employees: Low

Imsidolimab, Rosnilimab, ANB032

Anaptys Bio, Inc. is a clinical stage biotechnology company focused on developing therapeutic product candidates for inflammation and immuno-oncology indications. Their products target dermatological inflammatory diseases and other human inflammatory conditions.

Tags: antibody development, biotechnology, immuno-oncology, inflammation, therapeutics

Symbol: ANAB

Recent Price: $13.22

Industry: Biotechnology

CEO: Mr. Daniel R. Faga

Sector: Healthcare

Employees: 117

Address: 10770 Wateridge Circle, San Diego, CA 92121-5801

Phone: 858 362 6295

Last updated: 2024-12-31

Candel Therapeutics, Inc.

Candel Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CAN-2409, CAN-3110

Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer patients, with products like CAN-2409 and CAN-3110 in various clinical trial phases.

Tags: biopharmaceutical, cancer treatment, clinical trials, immunotherapies

Symbol: CADL

Recent Price: $7.95

Industry: Biotechnology

CEO: Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.

Sector: Healthcare

Employees: 42

Address: 117 Kendrick Street, Needham, MA 02494

Phone: 617 916 5445

Last updated: 2024-12-31

Ikena Oncology, Inc.

Ikena Oncology, Inc. logo
Market Cap: Low
Employees: Lowest

IK-930

Ikena Oncology is a targeted oncology company developing medicines tailored to biomarker-defined patient groups, with a focus on unmet needs in cancer treatment.

Tags: biomarkers, biotechnology, cancer treatment, oncology, pharmaceuticals

Symbol: IKNA

Recent Price: $1.60

Industry: Biotechnology

CEO: Dr. Mark Manfredi Ph.D.

Sector: Healthcare

Employees: 18

Address: 645 Summer Street, Boston, MA 02210

Phone: 857 273 8343

Last updated: 2024-12-31

INmune Bio, Inc.

INmune Bio, Inc. logo
Market Cap: Low
Employees: Lowest

INKmune

INmune Bio, Inc. is a clinical-stage immunotherapy company focused on developing drugs to reprogram the patient's innate immune system for the treatment of hematologic malignancies, solid tumors, chronic inflammation, and Alzheimer's disease.

Tags: Alzheimer's disease, chronic inflammation, hematologic malignancies, immunotherapy, solid tumors

Symbol: INMB

Recent Price: $4.65

Industry: Biotechnology

CEO: Dr. Raymond Joseph Tesi M.D.

Sector: Healthcare

Employees: 11

Address: 225 NE Mizner Boulevard, Boca Raton, FL 33432

Phone: 858 964 3720

Last updated: 2024-12-31

Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

zilovertamab, ONCT-216, ONCT-808, ONCT-534

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.

Tags: CAR-T, ROR1, antibody, biopharmaceutical, cancer therapy, clinical-stage, oncology

Symbol: ONCT

Recent Price: $0.53

Industry: Biotechnology

CEO: Dr. James B. Breitmeyer M.D., Ph.D.

Sector: Healthcare

Employees: 27

Address: 12230 El Camino Real, San Diego, CA 92130

Phone: 858 434 1113

Last updated: 2024-12-31

Pyxis Oncology, Inc.

Pyxis Oncology, Inc. logo
Market Cap: Low
Employees: Lowest

PYX-106, PYX-102, PYX-201, PYX-202, PYX-203

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, focuses on developing therapies to treat various cancers through immune-oncology and antibody drug conjugate product candidates.

Tags: antibody drug conjugate, biopharmaceutical, cancer therapy, immune-oncology, solid tumors

Symbol: PYXS

Recent Price: $1.56

Industry: Biotechnology

CEO: Dr. Lara S. Sullivan M.D., MBA

Sector: Healthcare

Employees: 55

Address: 35 Cambridgepark Drive, Cambridge, MA 02140

Phone: 617 221 9059

Last updated: 2024-12-31

ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc. logo
Market Cap: Low
Employees: Low

ALX148

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company developing therapies for cancer patients. Its lead product, ALX148, targets CD47 and is in trials for various cancers. The company also explores pre-clinical treatments like ALTA-002 to enhance immune response to cancer.

Tags: CD47, cancer therapy, clinical trials, collaboration, immuno-oncology, solid tumors

Symbol: ALXO

Recent Price: $1.66

Industry: Biotechnology

CEO: Mr. Jason W. Lettmann

Sector: Healthcare

Employees: 81

Address: 323 Allerton Avenue, South San Francisco, CA 94080

Phone: 650 466 7125

Last updated: 2024-12-31

Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Ik T-148009

Inhibikase Therapeutics, Inc. is a clinical stage pharmaceutical company focused on developing therapeutics for Parkinson's Disease and related disorders. Their product pipeline includes treatments for neurological and cancer-related conditions.

Tags: Cancer Treatment, Neurological Disorders, Parkinson's Disease, Pharmaceutical, Therapeutics

Symbol: IKT

Recent Price: $3.24

Industry: Biotechnology

CEO: Dr. Milton H. Werner Ph.D.

Sector: Healthcare

Employees: 8

Address: 3350 Riverwood Parkway SE, Atlanta, GA 30339

Phone: 678 392 3419

Leadership

  • Milton H. Werner, Ph.D., President and CEO
  • C. Warren Olanow MD, FRCPC, FRCP (Hon.), Medical Consultant and CEO of Clintrex Research Corporation
  • Garth Lees-Rolfe, CPA, Chief Financial Officer
  • Dan Williams, Controller
  • Terence Kelly, Ph.D., Medicinal Chemistry Consultant
  • Surendra Singh, Ph.D., Chemistry and Manufacturing Controls
  • Merrill M. Kraines, Partner, McDermott, Will & Emery, Outside General Counsel
  • Roberto Bellini, Managing Partner at BSQUARED Capital
  • Dennis Berman, Serial Entrepreneur
  • David Canner, Ph.D., Partner at Soleus Capital
  • Roy Freeman, M.D., Professor of Neurology at the Harvard Medical School, Director of the Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center
  • Arvind Kush, Chief Financial Officer and Chief Business Officer of Candid Therapeutics
  • Amit Munshi, Chief Executive Officer of Orna Therapeutics

Last updated: 2024-12-31

Immunome, Inc.

Immunome, Inc. logo
Market Cap: Medium
Employees: Low

IMM-ONC-01, IMM-BCP-01

Immunome, Inc. is a biopharmaceutical company focused on developing antibody therapeutics for oncology and infectious diseases, offering innovative solutions such as IMM-ONC-01 for cancer and IMM-BCP-01 for COVID-19 treatment.

Tags: antibody therapeutics, biopharmaceutical, infectious disease, oncology

Symbol: IMNM

Recent Price: $10.28

Industry: Biotechnology

CEO: Dr. Clay B. Siegall Ph.D.

Sector: Healthcare

Employees: 78

Address: 665 Stockton Drive, Exton, PA 19341

Phone: 610 321 3700

Last updated: 2024-12-31

Imunon, Inc.

Imunon, Inc. logo
Market Cap: Lowest
Employees: Lowest

GEN-1, Thermo Dox

Imunon, Inc. is a clinical stage biotechnology company specializing in the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies, focusing on products such as GEN-1 for ovarian cancer and Thermo Dox for various cancer indications.

Tags: Biotechnology, Cancer Treatment, DNA Therapies, Immunotherapy, Vaccines

Symbol: IMNN

Recent Price: $0.82

Industry: Biotechnology

CEO: Dr. Stacy R. Lindborg Ph.D.

Sector: Healthcare

Employees: 33

Address: 997 Lenox Drive, Lawrenceville, NJ 08648

Phone: 609 896 9100

Leadership

  • Stacy R. Lindborg, PhD, President, Chief Executive Officer, and Board Director
  • David Gaiero, Chief Financial Officer
  • Khursheed Anwer, PhD, MBA, Executive Vice President and Chief Science Officer
  • Kristin Longobardi, MBA, Senior Vice President, Strategic Operations
  • Susan Eylward, General Counsel and Corporate Secretary
  • Michael H. Tardugno,
  • Frederick J. Fritz,
  • Donald Braun, PhD,
  • Christine Pellizzari, JD,
  • James E. Dentzer,

Last updated: 2024-12-31

Immuneering Corporation

Immuneering Corporation logo
Market Cap: Lowest
Employees: Low

IMM-1-104 and IMM-6-415

Immuneering Corporation is a biopharmaceutical company focused on developing oncology and neuroscience product candidates, with key products like IMM-1-104 for cancer treatment and IMM-6-415 for solid tumors.

Tags: biopharmaceutical, cancer treatment, drug development, neuroscience, oncology

Symbol: IMRX

Recent Price: $2.25

Industry: Biotechnology

CEO: Dr. Benjamin J. Zeskind M.B.A., Ph.D.

Sector: Healthcare

Employees: 66

Address: 245 Main Street, Cambridge, MA 02142

Phone: 617 500 8080

Last updated: 2024-12-31

Incyte Corporation

Incyte Corporation logo
Market Cap: Highest
Employees: High

JAKAFI, PEMAZYRE, ICLUSIG

Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, with products like JAKAFI, PEMAZYRE, and ICLUSIG for various cancer treatments.

Tags: ICLUSIG, JAKAFI, PEMAZYRE, biopharmaceutical, cancer treatment, clinical trials, oncology, therapeutics

Symbol: INCY

Recent Price: $68.42

Industry: Biotechnology

CEO: Mr. Herve Hoppenot

Sector: Healthcare

Employees: 2524

Address: 1801 Augustine Cut-Off, Wilmington, DE 19803

Phone: 302 498 6700

Leadership

  • HervΓ© Hoppenot, Chairman and Chief Executive Officer
  • Paula J. Swain, Executive Vice President, Human Resources
  • Pablo J. Cagnoni, M.D., President, Head of Research and Development
  • Steven H. Stein, M.D., Executive Vice President and Chief Medical Officer
  • Sheila A. Denton, J.D., Executive Vice President and General Counsel
  • Christiana Stamoulis, MBA, Executive Vice President and Chief Financial Officer
  • Barry P. Flannelly, PharmD, MBA, Executive Vice President and General Manager, North America
  • Denise Brashear, Vice President, Head of Global Communications
  • Vijay Iyengar, M.D., Executive Vice President, Global Medical Affairs, Product, and Partnership Strategy (GMAP2S)
  • Lee Heeson, Executive Vice President, Head of Incyte International
  • Michael Morrissey, Executive Vice President and Head of Global Technical Operations
  • Matteo Trotta, MBA, Executive Vice President, General Manager, U.S. Dermatology
  • Xiaozhao Wang, Ph.D., Associate Vice President, Head of Medicinal Chemistry
  • Julian C. Baker, Managing Partner
  • Jean-Jacques Bienaime, Former Chief Executive Officer
  • Otis Brawley, M.D., Bloomberg Distinguished Professor of Oncology and Epidemiology
  • Paul J. Clancy, Former Executive Vice President and Senior Advisor
  • Jacqualyn A. Fouse, Ph.D., Former Chief Executive Officer
  • Edmund P. Harrigan, M.D., Former Senior Vice President of Worldwide Safety and Regulatory
  • Katherine High, M.D., Former President and Head of Research and Development
  • Susanne Schaffert, Ph.D., Former President

Last updated: 2024-12-31

Kura Oncology, Inc.

Kura Oncology, Inc. logo
Market Cap: High
Employees: Low

ziftomenib and tipifarnib

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company developing small molecule medicines for the treatment of cancer. It focuses on genetically defined subsets of acute leukemias and has a collaboration with Novartis for certain carcinoma treatments.

Tags: biopharmaceutical, cancer treatment, clinical trials, hematologic, leukemia, small molecule, solid tumors

Symbol: KURA

Recent Price: $8.51

Industry: Biotechnology

CEO: Dr. Troy Edward Wilson J.D., Ph.D.

Sector: Healthcare

Employees: 142

Address: 12730 High Bluff Drive, San Diego, CA 92130

Phone: 858 500 8800

Last updated: 2024-12-31

MediciNova, Inc.

MediciNova, Inc. logo
Market Cap: Low
Employees: Lowest

MN-166 (ibudilast)

Medici Nova, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious diseases with unmet medical needs, including neurologic disorders, fibrotic diseases, and solid tumor cancers.

Tags: United States, biopharmaceutical, fibrotic diseases, neurological disorders, novel therapeutics, solid tumors, unmet medical needs

Symbol: MNOV

Recent Price: $2.11

Industry: Biotechnology

CEO: Dr. Yuichi Iwaki M.D., Ph.D.

Sector: Healthcare

Employees: 13

Address: 4275 Executive Square, La Jolla, CA 92037

Phone: 858 373 1500

Leadership

  • Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer, and Founder
  • Kazuko Matsuda, M.D., Ph.D, MPH, Chief Medical Officer
  • David H. Crean, Ph.D., Chief Business Officer
  • Jason J. Kruger, CPA (inactive), Chief Financial Officer
  • Hideki Nagao, Member of the Board of Directors
  • Carolyn Beaver, Member of the Board of Directors
  • Nicole Lemerond, CFA, Member of the Board of Directors

Last updated: 2024-12-31

Nkarta, Inc.

Nkarta, Inc. logo
Market Cap: Low
Employees: Low

NKX101 and NKX019

Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cell therapies for the treatment of cancer. The company specializes in cellular immunotherapy using chimeric antigen receptors on natural killer cells to target tumor antigens.

Tags: NK cells, biopharmaceutical, cancer treatment, cell therapy, clinical trials, immunotherapy

Symbol: NKTX

Recent Price: $2.32

Industry: Biotechnology

CEO: Mr. Paul J. Hastings

Sector: Healthcare

Employees: 150

Address: 6000 Shoreline Court, South San Francisco, CA 94080

Phone: 415 582 4923

Last updated: 2024-12-31

Cullinan Oncology, Inc.

Cullinan Oncology, Inc. logo
Market Cap: Medium
Employees: Low

CLN-081

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Their lead candidate, CLN-081, is in a trial for treating non-small cell lung cancer. The company also has several preclinical products targeting various forms of cancer.

Tags: biopharmaceutical, cancer, clinical trials, immuno-oncology, oncology, therapies

Symbol: CGEM

Recent Price: $12.20

Industry: Biotechnology

CEO: Mr. Nadim Ahmed

Sector: Healthcare

Employees: 85

Address: One Main Street, Cambridge, MA 02142

Phone: 617 410 4650

Last updated: 2024-12-31

Immix Biopharma, Inc.

Immix Biopharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

IMX-110, IMX-111, IMX-120

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing tissue-specific therapeutics for oncology and inflammation, with clinical trials across the United States and Australia.

Tags: Biopharmaceuticals, Clinical Trials, Inflammation, Oncology, Tissue-Specific Therapeutics

Symbol: IMMX

Recent Price: $2.36

Industry: Biotechnology

CEO: Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.

Sector: Healthcare

Employees: 14

Address: 11400 West Olympic Boulevard, Los Angeles, CA 90064

Phone: 310 651 8041

Last updated: 2024-12-31

IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc. logo
Market Cap: High
Employees: Low

IDE397 and IDE196

IDEAYA Biosciences, Inc. is a precision medicine oncology company that focuses on developing targeted therapeutics for specific patient populations using molecular diagnostics. Key product candidates include IDE397 and IDE196, aimed at treating genetically defined cancers.

Tags: clinical trials, molecular diagnostics, oncology, precision medicine, synthetic lethality, targeted therapeutics

Symbol: IDYA

Recent Price: $24.93

Industry: Biotechnology

CEO: Mr. Yujiro S. Hata

Sector: Healthcare

Employees: 124

Address: 7000 Shoreline Court, South San Francisco, CA 94080

Phone: 650 443 6209

Last updated: 2024-12-31

The Oncology Institute, Inc.

The Oncology Institute, Inc. logo
Market Cap: Lowest
Employees: Medium

Medical Oncology Services

An oncology company providing medical oncology services in the United States, including clinical trials, radiation, outpatient stem cell transplants, and patient support, serving adult and senior cancer patients with 67 clinic locations.

Tags: Cancer Care, Clinical Trials, Medical Services, Oncology, Patient Support, Stem Cell Transplants

Symbol: TOI

Recent Price: $0.32

Industry: Medical - Care Facilities

CEO: Dr. Daniel Virnich FACHE, M.B.A., M.D.

Sector: Healthcare

Employees: 800

Address: 18000 Studebaker Road, Cerritos, CA 90703

Phone: 213 760 1328

Last updated: 2024-12-31

Tango Therapeutics, Inc.

Tango Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

TNG908

Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.

Tags: BRCA1/2-mutant cancers, Gilead Sciences, STK11-mutant cancers, TNG908, biotechnology, cancer treatment, drug development, methylthioadenosine phosphorylase, protein arginine methyltransferase 5, strategic collaboration, synthetic lethal

Symbol: TNGX

Recent Price: $3.10

Industry: Biotechnology

CEO: Dr. Barbara L. Weber M.D.

Sector: Healthcare

Employees: 140

Address: 100 Binney Street, Cambridge, MA 02142

Phone: 857 320 4900

Last updated: 2024-12-31